Inovio Pharmaceuticals, Inc. (INO)

$10.2

-0.87

(-7.86%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Inovio Pharmaceuticals, Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 388.44K → 102.65K (in $), with an average decrease of 73.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -35.53M → -25.00M (in $), with an average increase of 20.2% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 42.0%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 334.5%

Performance

  • $10.12
    $11.00
    $10.20
    downward going graph

    0.78%

    Downside

    Day's Volatility :8.0%

    Upside

    7.27%

    downward going graph
  • $3.89
    $14.75
    $10.20
    downward going graph

    61.86%

    Downside

    52 Weeks Volatility :73.63%

    Upside

    30.85%

    downward going graph

Returns

PeriodInovio Pharmaceuticals, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
28.12%
-0.7%
0.0%
6 Months
99.16%
6.6%
0.0%
1 Year
4.67%
3.7%
-1.5%
3 Years
-89.53%
14.0%
-21.8%

Highlights

Market Capitalization
225.2M
Book Value
$5.15
Earnings Per Share (EPS)
-6.09
PEG Ratio
0.0
Wall Street Target Price
19.25
Profit Margin
0.0%
Operating Margin TTM
-26686.29%
Return On Assets TTM
-32.11%
Return On Equity TTM
-79.55%
Revenue TTM
832.0K
Revenue Per Share TTM
0.04
Quarterly Revenue Growth YOY
-17.7%
Gross Profit TTM
-177.4M
EBITDA
-130.7M
Diluted Eps TTM
-6.09
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.93
EPS Estimate Next Year
-3.39
EPS Estimate Current Quarter
-1.27
EPS Estimate Next Quarter
-0.82

Analyst Recommendation

Hold
    0
    0%Buy
    54%Hold
    45%Sell
Based on 11 Wall street analysts offering stock ratings for Inovio Pharmaceuticals, Inc.(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
6
6
6
Sell
5
5
6

Analyst Forecast

What analysts predicted

Upside of 88.73%

Current $10.20
Target $19.25

Company Financials

FY18Y/Y Change
Revenue
30.5M
↓ 27.8%
Net Income
-97.0M
↑ 9.93%
Net Profit Margin
-318.12%
↓ 109.2%
FY19Y/Y Change
Revenue
4.1M
↓ 86.51%
Net Income
-120.6M
↑ 24.32%
Net Profit Margin
-2.9K%
↓ 2613.64%
FY20Y/Y Change
Revenue
7.4M
↑ 80.24%
Net Income
-215.1M
↑ 78.42%
Net Profit Margin
-2.9K%
↑ 29.59%
FY21Y/Y Change
Revenue
1.8M
↓ 76.05%
Net Income
-305.4M
↑ 41.98%
Net Profit Margin
-17.2K%
↓ 14304.96%
FY22Y/Y Change
Revenue
10.3M
↑ 478.23%
Net Income
-287.7M
↓ 5.8%
Net Profit Margin
-2.8K%
↑ 14404.0%
FY23Y/Y Change
Revenue
832.0K
↓ 91.89%
Net Income
-135.1M
↓ 53.03%
Net Profit Margin
-16.2K%
↓ 13436.74%
Q3 FY22Q/Q Change
Revenue
9.2M
↑ 1067.03%
Net Income
-39.6M
↓ 64.77%
Net Profit Margin
-432.78%
↑ 13904.95%
Q4 FY22Q/Q Change
Revenue
124.7K
↓ 98.64%
Net Income
-51.7M
↑ 30.42%
Net Profit Margin
-41.4K%
↓ 41012.59%
Q1 FY23Q/Q Change
Revenue
114.9K
↓ 7.8%
Net Income
2.9B
↓ 5807.03%
Net Profit Margin
2.6M%
↑ 2606824.46%
Q2 FY23Q/Q Change
Revenue
226.0K
↑ 96.59%
Net Income
-35.5M
↓ 101.21%
Net Profit Margin
-15.7K%
↓ 2581104.35%
Q3 FY23Q/Q Change
Revenue
388.4K
↑ 71.9%
Net Income
-33.9M
↓ 4.52%
Net Profit Margin
-8.7K%
↑ 6990.49%
Q4 FY23Q/Q Change
Revenue
102.7K
↓ 73.57%
Net Income
-25.0M
↓ 26.31%
Net Profit Margin
-24.4K%
↓ 15623.14%
FY18Y/Y Change
Total Assets
131.1M
↓ 29.98%
Total Liabilities
44.1M
↓ 1.5%
FY19Y/Y Change
Total Assets
144.0M
↑ 9.79%
Total Liabilities
138.5M
↑ 214.3%
FY20Y/Y Change
Total Assets
539.8M
↑ 274.97%
Total Liabilities
78.6M
↓ 43.25%
FY21Y/Y Change
Total Assets
495.9M
↓ 8.12%
Total Liabilities
96.3M
↑ 22.43%
FY22Y/Y Change
Total Assets
348.5M
↓ 29.72%
Total Liabilities
126.2M
↑ 31.06%
FY23Y/Y Change
Total Assets
172.9M
↓ 50.38%
Total Liabilities
55.6M
↓ 55.94%
Q3 FY22Q/Q Change
Total Assets
392.0M
↓ 14.68%
Total Liabilities
125.3M
↓ 22.54%
Q4 FY22Q/Q Change
Total Assets
348.5M
↓ 11.08%
Total Liabilities
126.2M
↑ 0.72%
Q1 FY23Q/Q Change
Total Assets
266.6M
↓ 23.51%
Total Liabilities
67.4M
↓ 46.6%
Q2 FY23Q/Q Change
Total Assets
233.0M
↓ 12.58%
Total Liabilities
63.7M
↓ 5.5%
Q3 FY23Q/Q Change
Total Assets
193.1M
↓ 17.14%
Total Liabilities
54.9M
↓ 13.71%
Q4 FY23Q/Q Change
Total Assets
172.9M
↓ 10.44%
Total Liabilities
55.6M
↑ 1.2%
FY18Y/Y Change
Operating Cash Flow
-73.6M
↑ 16.36%
Investing Cash Flow
42.4M
↓ 252.42%
Financing Cash Flow
31.0M
↓ 67.56%
FY19Y/Y Change
Operating Cash Flow
-97.9M
↑ 33.04%
Investing Cash Flow
-9.0M
↓ 121.32%
Financing Cash Flow
105.4M
↑ 239.58%
FY20Y/Y Change
Operating Cash Flow
-178.0M
↑ 81.89%
Investing Cash Flow
-58.8M
↑ 550.04%
Financing Cash Flow
465.3M
↑ 341.45%
FY21Y/Y Change
Operating Cash Flow
-215.7M
↑ 21.2%
Investing Cash Flow
-175.3M
↑ 198.23%
Financing Cash Flow
211.5M
↓ 54.54%
FY22Y/Y Change
Operating Cash Flow
-216.2M
↑ 0.23%
Investing Cash Flow
109.6M
↓ 162.5%
Financing Cash Flow
81.8M
↓ 61.3%
Q3 FY22Q/Q Change
Operating Cash Flow
-67.5M
↑ 33.52%
Investing Cash Flow
44.6M
↓ 532.42%
Financing Cash Flow
3.8M
↓ 91.12%
Q4 FY22Q/Q Change
Operating Cash Flow
-36.3M
↓ 46.14%
Investing Cash Flow
54.0M
↑ 21.2%
Financing Cash Flow
6.7M
↑ 74.94%
Q1 FY23Q/Q Change
Operating Cash Flow
-36.7M
↑ 0.89%
Investing Cash Flow
19.0M
↓ 64.82%
Financing Cash Flow
-424.7K
↓ 106.37%
Q2 FY23Q/Q Change
Operating Cash Flow
-32.3M
↓ 11.86%
Investing Cash Flow
53.9M
↑ 183.72%
Financing Cash Flow
2.9M
↓ 778.8%
Q3 FY23Q/Q Change
Operating Cash Flow
-36.8M
↑ 14.0%
Investing Cash Flow
-5.5M
↓ 110.19%
Financing Cash Flow
2.9M
↑ 1.12%

Technicals Summary

Sell

Neutral

Buy

Inovio Pharmaceuticals, Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc.
3.26%
99.16%
4.67%
-89.53%
-75.27%
Moderna, Inc.
Moderna, Inc.
-0.79%
20.27%
-27.48%
-36.11%
359.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.12%
9.1%
11.53%
80.35%
170.35%
Novo Nordisk A/s
Novo Nordisk A/s
-6.29%
23.82%
46.7%
242.59%
414.69%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.44%
6.95%
20.9%
79.35%
133.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc.
NA
NA
0.0
-3.93
-0.8
-0.32
NA
5.15
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.58
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc.
Hold
$225.2M
-75.27%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$39.8B
359.53%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
170.35%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
414.69%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.77%
28.42
36.68%

Institutional Holdings

  • Vanguard Group Inc

    7.16%

  • BlackRock Inc

    2.11%

  • D. E. Shaw & Co LP

    1.97%

  • Renaissance Technologies Corp

    1.74%

  • Millennium Management LLC

    1.63%

  • Geode Capital Management, LLC

    0.98%

Corporate Announcements

  • Inovio Pharmaceuticals, Inc. Earnings

    Inovio Pharmaceuticals, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

inovio is revolutionizing the fight against cancer and infectious diseases. our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. with an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. partners and collaborators include roche, medimmune, university of pennsylvania, darpa, drexel university, nih, hiv vaccines trial network, national cancer institute, u.s. military hiv research program, and university of manitoba. for more information, visit www.inovio.com.

Organization
Inovio Pharmaceuticals, Inc.
Employees
122
CEO
Dr. Jacqueline E. Shea Ph.D.
Industry
Health Technology

Discover More

FAQs